Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis

Company Overview

Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of tumor-infiltrating lymphocyte (TIL) therapies for patients with solid tumors. The company’s lead candidate, lifileucel, is a one-time, autologous TIL therapy engineered to enhance the body’s immune response against malignant cells. Iovance’s pipeline also includes additional TIL-based programs targeting indications such as cervical, head and neck, and non–small cell lung cancers.

Iovance designs its cell therapies using proprietary manufacturing processes that collect and expand patients’ own tumor-reactive T cells before reintroducing them to the body. The company operates a Good Manufacturing Practice (GMP) facility in Philadelphia and collaborates with a network of academic centers and contract manufacturers to support large-scale production. Clinical trials for lifileucel and other TIL candidates are underway in the United States and Europe, with regulatory filings planned in multiple jurisdictions.

Founded in 2007 as Genesis Biopharma and later merged with Lion Biotechnologies, the company rebranded as Iovance Biotherapeutics in 2021 to reflect its evolving pipeline and global ambitions. Headquartered in San Carlos, California, Iovance has established research alliances and clinical partnerships across North America, Europe and Australia. The company’s R&D activities are bolstered by collaborations with leading cancer centers and academic institutions specializing in immuno-oncology.

Iovance is led by a management team with deep expertise in cell therapy development, clinical oncology and regulatory affairs. The company’s senior leadership includes professionals who have guided multiple biologic product approvals and built substantial manufacturing infrastructures. An experienced board of directors and an advisory panel of immunotherapy pioneers support Iovance’s strategic direction as it advances toward potential commercial launches.

Key Stats

• Today's Range: $1.85 to $1.93
• 50-Day Range: $1.66 to $3.50
• 52-Week Range: $1.64 to $12.51
• Volume: 6.77 million shs
• Average Volume: 9.13 million shs
• Market Capitalization: $624.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.22
• Consensus Rating: Moderate Buy

Iovance Biotherapeutics Stock Analysis - MarketRank™

Iovance Biotherapeutics scored higher than 94% of companies evaluated by MarketBeat, and ranked 62nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Iovance Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Iovance Biotherapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($1.24) to ($0.88) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Iovance Biotherapeutics is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Iovance Biotherapeutics is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Iovance Biotherapeutics has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

35.65% of the float of Iovance Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Iovance Biotherapeutics has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Iovance Biotherapeutics has recently increased by 6.40%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Iovance Biotherapeutics does not currently pay a dividend.

Dividend Growth

Iovance Biotherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.12

Percentage of Shares Shorted

35.65% of the float of Iovance Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Iovance Biotherapeutics has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Iovance Biotherapeutics has recently increased by 6.40%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.14

News Sentiment

Iovance Biotherapeutics has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 44 news articles for Iovance Biotherapeutics this week, compared to 12 articles on an average week.

Search Interest

Only 34 people have searched for IOVA on MarketBeat in the last 30 days. This is a decrease of -6% compared to the previous 30 days.

MarketBeat Follows

Only 12 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Iovance Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,744.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

10.30% of the stock of Iovance Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

77.03% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IOVA Stock Analysis - Frequently Asked Questions

How have IOVA shares performed this year?

Iovance Biotherapeutics' stock was trading at $7.40 at the beginning of the year. Since then, IOVA shares have decreased by 74.7% and is now trading at $1.87.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) announced its earnings results on Thursday, May, 8th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by $0.11. Iovance Biotherapeutics's revenue was up 6795.1% compared to the same quarter last year.
Read the conference call transcript.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Iovance Biotherapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), CrowdStrike (CRWD) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IOVA
• CIK: 1425205
• Web: www.iovance.com
• Phone: (650) 260-7120
• Fax: N/A
• Employees: 500
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Iovance Biotherapeutics: $12.22
• High Price Target: $25.00
• Low Price Target: $2.00
• Potential Upside/Downside: +553.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$372.18 million
• Net Margins: -176.49%
• Pretax Margin: -178.02%
• Return on Equity: -49.71%
• Return on Assets: -39.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.18
• Quick Ratio: 3.64

Sales & Book Value

• Annual Sales: $212.68 million
• Price / Sales: 2.94
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.33 per share
• Price / Book: 0.80

Miscellaneous

• Outstanding Shares: 333,934,000
• Free Float: 299,539,000
• Market Cap: $624.46 million
• Optionable: Optionable
• Beta: 0.85